| 摘要 |
The invention relates to the use of endogenous metabolites to produce a metabolic profile of a disorder or disease in a subject, e.g. an autoimmune disease, in particular rheumatoid arthritis, and the analysis of such metabolic profiles in order to find disturbances in such profiles in a subject which are caused by or correlated with the said diseases or disorders. Such disturbances can be normalised by treatment of the subject with specified compounds, particularly N-(2-chloro-3,4-dimethoxybenzylideneamino) guanidine or an aminoguanidine. |
| 主权项 |
1. A method for normalising a disturbance in the metabolic profile of endogenous metabolites in a subject caused by rheumatoid arthritis (RA), the method comprising:
(i) measuring the levels of N endogenous metabolites in a biological sample obtained from the subject, wherein N is 11, in order to produce a metabolic profile of the N endogenous metabolites in that subject; (ii) comparing the measured levels of the N endogenous metabolites with the corresponding levels of the endogenous metabolites in a biological sample obtained from a control; wherein the N endogenous metabolites are selected from the group consisting of:EM1PhenylalanineEM2TyrosineEM3IsoleucineEM8GlycineEM9GlutamineEM10MethionineEM14LysineEM15AsparagineEM16SerineEM17TryptophanEM18Threonine wherein the disturbance in the metabolic profile is one wherein there is a decrease in the level of each of the N measured endogenous metabolites in the biological sample obtained from the subject compared to the corresponding levels of endogenous metabolites in the biological sample obtained from the control, and wherein the disturbance in the metabolic profile is due to RA in the subject, and if a disturbance in the metabolic profile is detected, (iiia) prescribing or supplying to the subject or recommending treatment of the subject with an effective amount of N-(2-chloro-3,4-dimethoxybenzylideneamino) guanidine, either as the free base or in salt form, for normalising the disturbed metabolic profile; or (iiib) administering to said subject an effective amount of N-(2-chloro-3,4-dimethoxybenzylideneamino) guanidine, either as the free base or in salt form, for normalising the disturbed metabolic profile. |
